TP53 oncogenic variants as prognostic factors in individuals with glioblastoma: a systematic review and meta-analysis
Por:
Esperante D., Galicia K.D., Rivas-Cuervo K.G., Cacho-Díaz B., Trejo-Becerril C., Taja-Chayeb L., Aboud O., Carlos-Escalante J.A., Wegman-Ostrosky T.
Publicada:
1 ene 2024
Resumen:
Background: This systematic review and meta-analysis investigated the relationship between somatic TP53 oncogenic variants and prognosis, specifically with overall survival (OS) and progression-free survival (PFS) in patients diagnosed with supratentorial glioblastoma. Methods: We included longitudinal studies and clinical trials involving a minimum of 40 adult participants diagnosed with supratentorial glioblastoma, wherein the status of TP53 variants was assessed. We conducted searches in multiple databases. We assessed bias risk using a modified version of the Quality in Prognosis Studies tool, and the certainty of evidence was evaluated following the principles of the GRADE approach. Results and conclusion: This study encompassed 23 papers involving 2,555 patients, out of which 716 had reported oncogenic variants. TP53 oncogenic variants were associated with a reduced likelihood of 1-year survival (OR 0.52, 95% CI 0.29–0.94). However, our analysis did not reveal any significant impact of TP53 variants on overall survival, progression-free survival, or 2-year survival. Therefore, this comprehensive analysis demonstrates that the presence of genetic variants in TP53 does not provide useful information for the prognosis of glioblastoma. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42021289496. Copyright © 2024 Esperante, Galicia, Rivas-Cuervo, Cacho-Díaz, Trejo-Becerril, Taja-Chayeb, Aboud, Carlos-Escalante and Wegman-Ostrosky.
Filiaciones:
Esperante D.:
Combined Studies Plan in Medicine (PECEM), Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
Faculty of Medicine, Universidad Nacional Autonoma de Mexico (UNAM), Mexico City, Mexico
Galicia K.D.:
Faculty of Superior Studies (FES) Iztacala, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
Rivas-Cuervo K.G.:
Fundación Gimnasio Moderno, Bogota, Colombia
Cacho-Díaz B.:
Neuro-oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico
Trejo-Becerril C.:
Precision Medicine Laboratory, Sub-Direction of Research Unit, INCan, Mexico City, Mexico
Taja-Chayeb L.:
Precision Medicine Laboratory, Sub-Direction of Research Unit, INCan, Mexico City, Mexico
Aboud O.:
Neuro-Oncology, Department of Neurology and Neurosurgery, UC Davis Comprehensive Cancer Center, Sacramento, CA, United States
Carlos-Escalante J.A.:
Combined Studies Plan in Medicine (PECEM), Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
Wegman-Ostrosky T.:
Precision Medicine Laboratory, Sub-Direction of Research Unit, INCan, Mexico City, Mexico
gold, All Open Access; Gold Open Access
|